| ID | 1253 |
| Name of the vaccine | V441 |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 6 to 8 weeks |
| Description of the vaccine | Diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine. |
| Name of the manufacturer | Merck Sharp & Dohme Corp. |
| Name of the manufacturing country | NA |
| Year of manufacture | 2003 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | NA |
| Mechanism of action | NA |
| Route of administration | NA |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For pertussis, tetanus, hepatitis B and poliomyelitis. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | NA |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT00092469 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|